Tecvayli (teclistamab-cqyv) / Genmab, J&J 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   2 News 


12345678910111213...1718»
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Journal, IO biomarker:  Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma. (Pubmed Central) -  Sep 25, 2024   
    Importantly, increasing TCE dose, the use of TCE against alternative targets (e.g.,GPRC5D), or gamma secretase inhibitors were able to overcome high sBCMA. These findings highlight the importance of accounting for baseline sBCMA levels, disease burden, and TCE dose intensity when administering anti-BCMA TCEs, offering critical insights for optimizing therapeutic strategies to overcome specific high-risk features and primary anti-BCMA TCE refractoriness.
  • ||||||||||  Next-Generation Novel Therapies in Multiple Myeloma (Room D (1F)) -  Sep 24, 2024 - Abstract #ICBMT2024ICBMT_137;    
    A wealth of therapeutic options have been approved for the treatment of newly diagnosed (ND) and relapsed/refractory (RR) multiple myeloma (MM) over the past two decades, with proteasome inhibitors (bortezomib, carfilzomib, ixazomib), immunomodulatory drugs (IMiDs; thalidomide, lenalidomide, pomalidomide), and monoclonal antibodies (mAbs; including the CD38 mAbs daratumumab and isatuximab, as well as the SLAMF7-targeting mAb elotuzumab) currently forming the backbone of treatment approaches in each setting. Additional targeted therapies have further enhanced the armamentarium, including, previously, the histone deacetylase inhibitor panobinostat, and, more recently, the nuclear export inhibitor selinexor 1 and the peptide
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J, iberdomide (CC-220) / BMS
    Trial completion date, Trial primary completion date, Combination therapy:  Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Hard-to-Treat Multiple Myeloma (clinicaltrials.gov) -  Sep 19, 2024   
    P1,  N=20, Not yet recruiting, 
    Additional targeted therapies have further enhanced the armamentarium, including, previously, the histone deacetylase inhibitor panobinostat, and, more recently, the nuclear export inhibitor selinexor 1 and the peptide Trial completion date: Jan 2027 --> Sep 2026 | Trial primary completion date: Jan 2027 --> Sep 2026
  • ||||||||||  MM Therapy in Resource-Constrained Including Maintenance () -  Aug 30, 2024 - Abstract #SOHO2024SOHO_1047;    
    In the public sector, for first-line patients eligible for ASCT in the induction phase, the option is VTd or VCd, followed by ASCT and then followed by consolidation or not and thalidomide maintenance, due to lenalidomide not being incorporated in the public sector...Unfortunately, the difference in treatments between public and private institutions leads to a lower OS in the public ones. To improve the management of MM patients in LMICs, additional novel agents and their facilitated access are imperative and further discussion on policy and pricing for these is most warranted.
  • ||||||||||  Bispecific T-Cell Engagers: Sequencing, BCMA, GPRC5D, and Resistance () -  Aug 30, 2024 - Abstract #SOHO2024SOHO_1046;    
    Currently, both FDA-approved CAR T-cell therapies, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), target the B-cell maturation antigen (BCMA) receptor on the surface of MM cells, and two of the FDA-approved bispecific antibodies, teclistamab and elranatamab, also target BCMA...Early clinical results indicate relatively encouraging response rates from teclistamab and elranatamb post-CAR T-cell therapy,6,7 and one retrospective study suggests a relatively prolonged benefit from bispecific antibodies in general.8 However, another retrospective study indicates that PFS may be limited.9 Although antigen escape may not be central when other targets are chosen, as with talquetamab, other mechanisms, including immune exhaustion that may also occur with bispecific antibodies, anti-CAR antibodies, and alterations in the tumor microenvironment, can have a detrimental impact on later lines of therapy...Ultimately, to comprehensively answer the sequencing question, the field requires prospective studies with adequate follow-up as well as banking and analysis of tumor and non-tumor specimens. As BCMA-directed CAR T-cell therapies are now approved in the earlier stages of disease, including at first relapse, this question is even more urgent.
  • ||||||||||  Treatment of Early Relapse: Non-CAR T Cells () -  Aug 30, 2024 - Abstract #SOHO2024SOHO_1045;    
    Patient and treatment characteristics of the firstline therapy should guide the optimal therapeutic choice at first relapse and thereafter. The sequencing of novel immunotherapies at relapse remains to be determined in upcoming clinical trials and real-world studies.
  • ||||||||||  The Role of Maintenance Therapy in the Treatment of Newly Diagnosed Multiple Myeloma () -  Aug 30, 2024 - Abstract #SOHO2024SOHO_1030;    
    P1, P1/2,
    Additionally, studies assessing the efficacy and safety of iberdomide (NCT06179888) and mezigdomide (NCT06048250) as maintenance agents post idecabtagene vicleucel are underway...Furthermore, a distinct benefit to patients currently receiving CAR-T is the possibility of experiencing a prolonged treatment-free interval afterwards,25 and the routine prescription of maintenance will change this radically. Moreover, maintenance therapy after CAR-T may also lead to increased patient financial toxicity and increase financial burdens on health care systems,26 noting the already high cost of CAR-T therapies.
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Complete Remission After Teclistamab Treatment in Multiple Myeloma: Case Report (LEVEL 3, HALL B3) -  Aug 30, 2024 - Abstract #SOHO2024SOHO_868;    
    Subsequently, due to disease progression, lenalidomidedexamethasone was initiated for a total of 6 cycles where lenalidomide was 15 mg given on d1/d21, resulting in a serological stable disease. As the disease further advanced with hypercalcemia, renal impairment, anemia, bone pain, and elevated lambda serum free light chains (lambda SFLCs) in April 2021, a third-line treatment regimen consisting of isatuximab-pomalidomidedexamethasone with zoledronic acid was initiated...Notably, no signs of cytokine release syndrome or immune effector cell
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Teclistamab Success in CAR-T Refractory Multiple Myeloma: A Case Presentation (LEVEL 3, HALL B3) -  Aug 30, 2024 - Abstract #SOHO2024SOHO_862;    
    She developed cytokine-release-syndrome (CRS), for which she received tocilizumab and 3 days of dexamethasone in ICU...She received subcutaneous denosumab 120 mg for bone disease... Prospective trials are needed to determine the optimal timing and use of teclistamab and other T-cell-redirecting therapies to increase the likelihood of cure for patients with myeloma.
  • ||||||||||  BTK Inhibitors: A Double-Edged (LEVEL 3, HALL B3) -  Aug 30, 2024 - Abstract #SOHO2024SOHO_519;    
    Despite the rarity of PBL in patients with CLL, this case underscores the importance of considering the potential for transformation, especially with the widespread use of BTKis. Further research is essential to elucidate the molecular mechanisms driving this transformation, facilitating the development of optimized treatment strategies and improving outcomes for patients with CLL at risk of PBL development.
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Journal:  Teclistamab-Associated Sclerouveitis with Hypopyon. (Pubmed Central) -  Aug 23, 2024   
    Further research is essential to elucidate the molecular mechanisms driving this transformation, facilitating the development of optimized treatment strategies and improving outcomes for patients with CLL at risk of PBL development. Teclistamab, a novel bispecific antibody recently approved for the treatment of relapsed or refractory multiple myeloma, may be associated with sclerouveitis with hypopyon.
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Journal:  Immunotherapy: the teclistamab fitness test. (Pubmed Central) -  Aug 8, 2024   
    Recruiting --> Active, not recruiting | N=152 --> 74 No abstract available
  • ||||||||||  Elrexfio (elranatamab-bcmm) / Pfizer, Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Review, Journal:  Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy. (Pubmed Central) -  Jun 28, 2024   
    The approval of elranatamab and teclistamab represents the next step in the development of bsAbs for the treatment of MM. This review article addresses the antigen targeting, efficacy, safety, and strategies in the application of bsAbs against treatment-resistant MM, with a focus on clinical trials and real-world data.
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J, Carvykti (ciltacabtagene autoleucel) / J&J, Blenrep (belantamab mafodotin-blmf) / GSK
    Journal, IO biomarker:  Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma. (Pubmed Central) -  May 10, 2024   
    Low-to-undetectable peripheral blood soluble BCMA levels correlated with the absence of BCMA expression by bone marrow plasma cells. Thus, although rare, loss of BCMA expression following TNFRSF17 gene deletions can occur following any BCMA-directed therapy and prevents response to subsequent anti-BCMA-directed treatments, underscoring the importance of verifying the presence of a target antigen.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Outcomes of ide-cel in patients with relapsed/refractory multiple myeloma: A single-institution experience. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_6459;    
    We did not find any significant predictive factors of PFS or OS with the caveat of a small sample size. Further research remains necessary to identify potential predictors that may discriminate responders from non-responders, which will improve the application of CAR T-cell therapy in patients with RRMM.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Associations of T-cell fitness prior to B-cell maturation antigen (BCMA) (Hall A; Poster Bd #: 186) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4074;    
    One limitation was a small sample size and thus testing PSI in a larger cohort might yield statistically significant results. The NR group had more high-risk cytogenetics and higher EM.